INVESTABOT
Equity Research
XNAS · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Amgen (AMGN) had 1 Form 144 pre-sale notice filed on 2026-08-06. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Amgen (AMGN) had 1 Form 144 pre-sale notice filed on 2026-08-11. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Amgen (AMGN) had 1 Form 144 pre-sale notice filed on 2026-08-13. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
Amgen (AMGN) had 1 Form 144 pre-sale notice filed on 2026-05-04. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction.
TL;DR: Amgen announced CFO Peter Griffith's retirement after six years in the role, with Thomas Dittrich set to take over as CFO on September 1, 2026. The transition is planned and structured, with Griffith staying…
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 3 unique sellers · 7 accumulating - 5 trimming - 1 unchanged
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| August 13, 2026 | Khosla Rachna | SVP, Business Development | OPTION_EXERCISE | 1,252 | $163 | ~$0.2M |
| August 13, 2026 | Khosla Rachna | SVP, Business Development | SELL | -1,252 | $416 | ~$0.5M |
| August 13, 2026 | Khosla Rachna | SVP, Business Development | OPTION_EXERCISE | -1,252 | — | — |
| August 11, 2026 | Khosla Rachna | SVP, Business Development | SELL | -2,000 | $413 | ~$0.8M |
| August 7, 2026 | Drake Michael V | — | GRANT | 63.88 | — | — |
| August 7, 2026 | Ishrak Omar | — | GRANT | 85.17 | — | — |
| August 7, 2026 | Holley Charles M | — | GRANT | 103.42 | — | — |
| August 7, 2026 | Busch Matthew C. | VP, Finance & CAO | GRANT | 730 | — | — |
| August 6, 2026 | Miller Derek | SVP, Human Resources | OPTION_EXERCISE | 2,069 | $163 | ~$0.3M |
| August 6, 2026 | Miller Derek | SVP, Human Resources | SELL | -2,069 | $403 | ~$0.8M |
| August 6, 2026 | Miller Derek | SVP, Human Resources | OPTION_EXERCISE | 1,821 | $177 | ~$0.3M |
| August 6, 2026 | Miller Derek | SVP, Human Resources | SELL | -1,821 | $403 | ~$0.7M |
| August 6, 2026 | Miller Derek | SVP, Human Resources | OPTION_EXERCISE | -2,069 | — | — |
| August 6, 2026 | Miller Derek | SVP, Human Resources | OPTION_EXERCISE | -1,821 | — | — |
| August 6, 2026 | Grygiel Nancy A. | SVP & CCO | OPTION_EXERCISE | 1,970 | $177 | ~$0.3M |
| August 6, 2026 | Grygiel Nancy A. | SVP & CCO | SELL | -1,970 | $402 | ~$0.8M |
| August 6, 2026 | Grygiel Nancy A. | SVP & CCO | OPTION_EXERCISE | 1,000 | $177 | ~$0.2M |
| August 6, 2026 | Grygiel Nancy A. | SVP & CCO | SELL | -1,000 | $402 | ~$0.4M |
| August 6, 2026 | Grygiel Nancy A. | SVP & CCO | OPTION_EXERCISE | -1,970 | — | — |
| August 6, 2026 | Grygiel Nancy A. | SVP & CCO | OPTION_EXERCISE | -1,000 | — | — |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| September 4, 2026 | — | — | — | — | SEC |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 54,838,826 | ~$17.9B | — | January 29, 2026 |
| BlackRock | 49,362,016 | ~$17.9B | 4.8% | August 7, 2026 |
| BlackRock | 47,100,472 | ~$16.6B | -0.6% | May 13, 2026 |
| BlackRock | 47,396,138 | ~$15.5B | — | February 12, 2026 |
| BlackRock | 46,042,729 | ~$14.4B | — | August 13, 2024 |
| State Street | 30,560,537 | ~$11.1B | 0.0% | August 7, 2026 |
| State Street | 30,548,488 | ~$10.7B | -0.1% | May 15, 2026 |
| State Street | 30,591,403 | ~$10.0B | — | February 13, 2026 |
| Morgan Stanley | 15,836,058 | ~$5.6B | 0.6% | May 15, 2026 |
| Morgan Stanley | 15,744,528 | ~$5.2B | — | May 27, 2026 |
| Morgan Stanley | 13,653,692 | ~$4.9B | -13.8% | August 13, 2026 |
| JP Morgan Chase | 7,437,937 | ~$2.6B | 212.0% | May 13, 2026 |
| Goldman Sachs | 4,559,332 | ~$1.7B | 3.2% | August 14, 2026 |
| Goldman Sachs | 4,417,289 | ~$1.6B | -4.0% | May 15, 2026 |
| Goldman Sachs | 4,600,358 | ~$1.5B | — | March 25, 2026 |
| JP Morgan Chase | 3,971,184 | ~$1.4B | -46.6% | August 12, 2026 |
| Fidelity (FMR) | 3,776,430 | ~$1.3B | 5.1% | May 15, 2026 |
| Fidelity (FMR) | 3,491,822 | ~$1.3B | -7.5% | August 13, 2026 |
| Fidelity (FMR) | 3,592,220 | ~$1.2B | — | February 17, 2026 |
| Citadel Advisors | 2,469,384 | ~$894.2M | 59.9% | August 14, 2026 |